COMMUNIQUÉS West-GlobeNewswire

Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections by FDA
04/01/2019
-PDUFA action date set for June 30, 2019- DUBLIN, Ireland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of [...]
Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
04/01/2019
GAITHERSBURG, Md., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed [...]
OraSure Technologies, Inc. Announces Two Acquisitions and Reaffirms Fourth Quarter 2018 Guidance
04/01/2019
CoreBiome leverages OraSure’s leadership position in microbiome sample collection with end-to-end laboratory services for sample processing, sequencing, and bioinformatics Novosanis’ urine collection technology expands [...]
Vistin Pharma ASA : Trading update for Energy Trading
04/01/2019
Oslo, Norway, 4 January 2019 Reference is made to the announcement yesterday regarding the resignation of Torbjørn Kjus, Head of Energy Trading at Vistin Pharma ASA ("Vistin Pharma" or the "Company"). The Company is in [...]
Zealand Pharma to attend JP Morgan Healthcare Conference and Oddo BHF Forum
04/01/2019
Press release – No. 2 / 2019 Zealand Pharma to attend JP Morgan Healthcare Conference and Oddo BHF Forum Copenhagen, January 4, 2019 – Britt Meelby Jensen, President and Chief Executive Officer of Zealand Pharma, Mats [...]
Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
04/01/2019
-- Initial Clinical Data Expected in First Half of 2020 -- CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a [...]
Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis
04/01/2019
Published online in SAGE Open Medicine on December 17, 2018 CORAL GABLES, Fla., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on [...]
Ovid Therapeutics Outlines 2019 Clinical and Business Priorities
04/01/2019
-- OV101 in Angelman syndrome : Pivotal Phase 3 NEPTUNE trial expected to begin in second half 2019 -- -- OV101 in Fragile X syndrome : Phase 2 ROCKET clinical trial results in adolescents and young adults expected in [...]
Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference
04/01/2019
- Updated clinical data from Phase 2 basket studies evaluating setmelanotide in Bardet-Biedl Syndrome (BBS) show continued weight loss for additional two patients at longer-term follow-up – - Pivotal Phase 3 clinical [...]
Dr. Tommaso Addona, MD, FACS Named President of Long Island Plastic Surgical Group
04/01/2019
Garden City, New York, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Dr. Tommaso Addona , Chief of Plastic Surgery at St. Joseph Hospital in Bethpage, and partner at Long Island Plastic Surgical Group (LIPSG), has been named the [...]
Tyme Announces the Presentation of SM-88 Data at the 2019 ASCO Genitourinary Cancers Symposium
04/01/2019
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will present clinical data [...]
Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
04/01/2019
-- Alexey Margolin, Ph.D. to Transition to Chairman of the Board -- -- URIROX-2™ Initiated; URIROX-1™ Topline Data Expected in Second Half of 2019 -- -- Multiple Catalysts Expected Across Pipeline in 2019 -- NEWTON, [...]
BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
04/01/2019
ALAMEDA, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A [...]
Shockwave Announces Appointment of Ray Larkin as Chairman of the Board
04/01/2019
SANTA CLARA, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical (“Shockwave”), a pioneer in the development and commercialization of intravascular lithotripsy to treat complex calcified cardiovascular disease, [...]
Canada House Announces Further Details of Vegreville Acquisition and Second Tranche of Funding from Alumina Partners
04/01/2019
TORONTO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Last month, Canada House Wellness Group Inc. (“Canada House” or the “Company”) was pleased to announce the acquisition through its wholly owned subsidiary Abba Medix Corp., of [...]
Result of General Meeting
04/01/2019
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Result of General Meeting Oxford, UK, and Cambridge, MA, US, 4 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic [...]
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
04/01/2019
EXTON, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 [...]
Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference
04/01/2019
DURHAM, N.C., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D [...]
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
04/01/2019
Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to [...]

Pages